Universitaet Stuttgart

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Universitãt Stuttgart

Baliopharm Ag

Universitat of Stuttgart

Peter Scheurich

Klaus Pfizenmaier

Roland Kontermann

Herwig Brunner

Thomas Schiestel

Matthias Grell

Ingo Grunwald

Andreas Herrmann

Fabian Richter

Kirstin Zettlitz

Günter Tovar

Sabine Muenkel

Anja Krippner-Heidenreich

Sabine Münkel

Angela Hammer

The invention provides for an inhibitor of the huTNFRI receptor which is a human or humanized antibody construct that monovalently recognizes huTNFRI through an antigen-binding moiety, which is characterized by specific CDR sequences, a pharmaceutical preparation thereof, method of producing the inhibitor and the medical use of the inhibitor.

Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof

The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1.

huTNFR1 selective antagonists

The invention relates to polypeptides comprising, as constituent A, at least three monomers of a member of the TNF ligand family and, as constituent B, at least two peptide linkers that link the monomers of the member of the TNF ligand family to one another. The invention also relates to the use of these polypeptides for treating diseases and for producing a medicament or a vaccine. The invention also relates to methods for producing and isolating these polypeptides, to nucleic acids that code for these polypeptides, to vectors containing these nucleic acids, to host cells transfected with these vectors, and to pharmaceutical compositions containing these inventive objects. Finally, the invention relates to methods for the extracorporeal manipulation, depletion and/or removal of components contained in body fluids, e.g. by means of apheresis.

Recombinant polypeptides of the members of the TNF ligand family and use thereof

The present invention relates to nanoparticles with tumor necrosis factor (TNF) or cytokine immobilized thereon, where TNF or the cytokine is preferably immobilized in the form of a trimer in directed fashion and with retention of its biological activity on the carrier, to methods for the directed immobilization of TNF or cytokine on nanoparticles, to the use of the nanoparticles having immobilized TNF or cytokine for the identification and/or isolation of cytokine- or TNF-binding partners and for the identification and/or isolation of inhibitors of the interaction between TNF or cytokine and its binding partners, to the use of such nanoparticles for preparing a pharmaceutical composition, in particular for the therapy of tumors, and to pharmaceutical and diagnostic compositions which comprise such nanoparticles.

Nanoparticles comprising biologically active TNF which is immobilized on the same

Growing community of inventors

Stuttgart, Germany

Peter Scheurich